Hillerod Hospital
- Address
- Dyrehavevej 29, 3400 Hillerød, Denmark
Infectious Diseases
The department focuses on viral and bacterial infections, aiming to improve treatment options and patient outcomes across a range of serious illnesses.
- HSV-2 meningitis – evaluating antiviral therapy effectiveness.
- COVID-19 in high‑risk non‑hospitalized adults – testing oral antivirals.
- Staphylococcus aureus bacteremia – comparing short versus extended antibiotic courses.
- Sepsis and septic shock – assessing empirical antibiotic strategies in intensive care.
- Chronic rhinosinusitis without nasal polyps – investigating novel anti‑inflammatory agents.
These studies seek to refine diagnostics, reduce mortality, and enhance quality of care for patients facing infectious threats.
Oncology
Research in the oncology field targets breast cancer subtypes, exploring new targeted therapies and combination regimens to extend survival.
- HR+/HER2‑ advanced/metastatic breast cancer – testing kinase inhibitors with endocrine therapy.
- HER2‑positive metastatic breast cancer – evaluating antibody‑drug conjugates, with and without brain metastases.
- Node‑positive estrogen receptor‑positive early breast cancer – assessing novel endocrine agents for recurrence prevention.
The goal is to demonstrate superior disease control and improve long‑term outcomes for women and men affected by breast cancer.
Gastroenterology
The site conducts trials in inflammatory bowel disease, focusing on both ulcerative colitis and Crohn’s disease to find safer, more effective treatments.
- Moderately to severely active Crohn's disease – oral selective inhibitors evaluated for remission.
- Moderately to severely active ulcerative colitis – endoscopic response and clinical remission as primary endpoints.
Long‑term safety and tolerability are also examined to support sustained disease management.
Cardiology
Cardiovascular research addresses chronic heart failure, seeking interventions that lower mortality and reduce hospital admissions.
- Chronic heart failure with reduced ejection fraction – testing hydralazine‑ISDN and metformin as adjunct therapies.
By targeting neuro‑hormonal pathways and metabolic modulation, these trials aim to improve functional capacity and survival.
Orthopedics
Orthopedic investigations evaluate pain management and functional recovery for common fracture injuries.
- Distal radius fracture – ultrasound‑guided brachial plexus nerve block compared with standard care.
The study measures analgesic effectiveness and facilitates early mobilization after closed reduction.
Critical Care
The intensive care platform explores best practices for patients admitted with life‑threatening conditions, aiming to standardize care across clinicians.
- Acute critical illness requiring ICU admission – platform trial assessing varied interventions.
- Sepsis and septic shock – evaluating mortality and organ support outcomes.
Findings are intended to inform evidence‑based protocols and improve survival rates in the ICU setting.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 17 therapeutic areas and 15 of 192 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 167 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
- 1Region Hovedstaden7active
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Region Hovedstaden9trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hillerod Hospital
lock Showing 1 of 50 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps – The BiRCh Study | Insmed Inc. | Phase II | Not Recruiting | May 2024 | Oct 2025 |
IMP list
lock Showing 1 of 192 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 4 | Unknown | 2023-01-12 | 2025-05-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
